Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
Business Wire•12/11/2026•16:00 ET
0
Key Highlights
- ➤$279.4 million cash, investments expected to fund operations into Q3 2028
- ➤FDA alignment sets 12-patient pivotal Phase 2 path for RP-A501
- ➤RP-A501 pivotal trial dosing expected complete by mid-2027
- ➤Dosing initiated in Phase 1 trial of RP-A701 for BAG3-DCM
- ➤KRESLADI commercial readiness achieved; two Qualified Treatment Centers activated
Expert Statements
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
“We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM.”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
“Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children.”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
“Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027
Get started
Create a free account to read the full story.